JOP20210138B1 - طرق علاج السرطان في نماذج تأوي طفرات esr1 - Google Patents

طرق علاج السرطان في نماذج تأوي طفرات esr1

Info

Publication number
JOP20210138B1
JOP20210138B1 JOJO/P/2021/0138A JOP20210138A JOP20210138B1 JO P20210138 B1 JOP20210138 B1 JO P20210138B1 JO P20210138 A JOP20210138 A JO P20210138A JO P20210138 B1 JOP20210138 B1 JO P20210138B1
Authority
JO
Jordan
Prior art keywords
estrogen receptor
alpha
cancer treatment
treatment approaches
models
Prior art date
Application number
JOJO/P/2021/0138A
Other languages
Arabic (ar)
English (en)
Inventor
Heike Arlt
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of JOP20210138A1 publication Critical patent/JOP20210138A1/ar
Application granted granted Critical
Publication of JOP20210138B1 publication Critical patent/JOP20210138B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JOJO/P/2021/0138A 2018-12-06 2021-06-06 طرق علاج السرطان في نماذج تأوي طفرات esr1 JOP20210138B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862776338P 2018-12-06 2018-12-06
PCT/US2019/064980 WO2020118202A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Publications (2)

Publication Number Publication Date
JOP20210138A1 JOP20210138A1 (ar) 2023-01-30
JOP20210138B1 true JOP20210138B1 (ar) 2025-10-01

Family

ID=69158304

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2021/0138A JOP20210138B1 (ar) 2018-12-06 2021-06-06 طرق علاج السرطان في نماذج تأوي طفرات esr1

Country Status (17)

Country Link
US (2) US20220016052A1 (https=)
EP (1) EP3890835A1 (https=)
JP (2) JP7497353B2 (https=)
KR (1) KR20210100135A (https=)
AU (1) AU2019392908B2 (https=)
BR (1) BR112021010141A2 (https=)
CA (1) CA3121918A1 (https=)
EA (1) EA202191256A1 (https=)
IL (1) IL283655A (https=)
JO (1) JOP20210138B1 (https=)
MA (1) MA54393A (https=)
MX (1) MX2021006412A (https=)
MY (1) MY208702A (https=)
PH (1) PH12021551327A1 (https=)
SG (1) SG11202105915UA (https=)
UA (1) UA129588C2 (https=)
WO (1) WO2020118202A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3834824T3 (fi) * 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
JP7019422B2 (ja) * 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法

Also Published As

Publication number Publication date
EP3890835A1 (en) 2021-10-13
JP2022511497A (ja) 2022-01-31
KR20210100135A (ko) 2021-08-13
IL283655A (en) 2021-07-29
CA3121918A1 (en) 2020-06-11
AU2019392908A1 (en) 2021-06-10
MX2021006412A (es) 2021-07-21
WO2020118202A1 (en) 2020-06-11
MY208702A (en) 2025-05-25
JP2024101017A (ja) 2024-07-26
BR112021010141A2 (pt) 2021-08-24
UA129588C2 (uk) 2025-06-11
US20220016052A1 (en) 2022-01-20
JP7497353B2 (ja) 2024-06-10
SG11202105915UA (en) 2021-07-29
MA54393A (fr) 2021-10-13
US20250241875A1 (en) 2025-07-31
JOP20210138A1 (ar) 2023-01-30
EA202191256A1 (ru) 2021-10-06
AU2019392908B2 (en) 2025-02-20
PH12021551327A1 (en) 2022-04-25

Similar Documents

Publication Publication Date Title
JOP20210137B1 (ar) طرق علاج سرطان مقاومة لمثبطات cdk4/6
EA202191958A1 (ru) Способы и соединения
MX419719B (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
HRP20210200T1 (hr) Kombinirana antitumorska imunoterapija
RU2017140674A (ru) Способы лечения рака
EP4589014A3 (en) Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
EA201991622A1 (ru) Комплексная терапия для лечения рака
PH12016502354A1 (en) Pharmaceutical composition
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
PH12019501896A1 (en) Therapeutic dendrimers
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2016011698A (es) Metodos y composiciones para modular mutantes de receptor de estrogeno.
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
ZA201907225B (en) Treatment of her2 positive cancers
EP4286008A3 (en) Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors
PH12020552223A1 (en) Activators of the unfolded protein response
JP2019532047A5 (https=)
MX385589B (es) RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM.
EA202092036A1 (ru) Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a
WO2014130932A3 (en) Novel androgen receptor mutation
MX2020011453A (es) Combinaciones para tratar el cancer.
PH12019500075A1 (en) Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders